ProfileGDS5678 / 1454041_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 22% 21% 21% 21% 20% 26% 21% 21% 21% 21% 21% 21% 29% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5377122
GSM967853U87-EV human glioblastoma xenograft - Control 22.4945921
GSM967854U87-EV human glioblastoma xenograft - Control 32.4972921
GSM967855U87-EV human glioblastoma xenograft - Control 42.4409721
GSM967856U87-EV human glioblastoma xenograft - Control 52.4381120
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6613226
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5298521
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4730621
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4681621
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4859921
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4873921
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4658121
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6578829
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4866621